Guardant Health (GH) CPO reports RSU vesting and tax sale on Form 4 filing

Rhea-AI Filing Summary

Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported equity compensation activity and related tax withholding. On 01/15/2026, 17,379 restricted stock units vested and were converted into common stock at an exercise price of $0, increasing her directly held common shares to 38,369 immediately after the conversion. The same day, 8,808 of those shares were withheld and disposed of at $111.98 per share to cover tax obligations associated with the vesting, leaving her with 29,561 shares of common stock held directly. The vested restricted stock units stem from an award granted on February 26, 2024 that vests over three years, with 33% vesting on the one-year anniversary of January 15, 2024 and the remaining 67% vesting in equal annual installments over the following two years.

Insider Trade Summary

17,379 shares exercised/converted

Mixed 3 txns

Insider Monroe Terilyn J.

Role Chief People Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	17,379	$0.00	--
Exercise	Common Stock	17,379	$0.00	--
Tax Withholding	Common Stock	8,808	$111.98	$986K

Holdings After Transaction: Restricted Stock Units — 17,379 shares (Direct); Common Stock — 38,369 shares (Direct)

Footnotes (1)

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. This represents a restricted stock unit award granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on the one-year anniversary of January 15, 2024 and the remaining 67% of the shares vest annually over the remaining two-year period, thereafter. Not applicable for Restricted Stock Units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monroe Terilyn J.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		M		17,379	A	$0	38,369	D
Common Stock	01/15/2026		F		8,808(1)	D	$111.98	29,561	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	01/15/2026		M			17,379	(2)	(3)	Common Stock	17,379	$0	17,379	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on the one-year anniversary of January 15, 2024 and the remaining 67% of the shares vest annually over the remaining two-year period, thereafter.

3. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Tarilyn J. Monroe	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Guardant Health (GH) report for Terilyn J. Monroe?

Guardant Health reported that Chief People Officer Terilyn J. Monroe had 17,379 restricted stock units vest and convert into common stock on 01/15/2026, along with a related share withholding to cover taxes.

How many Guardant Health shares were withheld for taxes in this Form 4?

The company retained 8,808 shares of common stock at a price of $111.98 per share to satisfy tax withholding obligations tied to the restricted stock unit vesting.

How many Guardant Health shares does Terilyn J. Monroe hold after the reported transactions?

Following the vesting and tax withholding transactions on 01/15/2026, Terilyn J. Monroe directly beneficially owns 29,561 shares of Guardant Health common stock.

What was the size and nature of the vested award for Guardant Health’s CPO?

The vested portion involved 17,379 restricted stock units that converted into common stock at an exercise price of $0, as part of an equity compensation award.

When was the underlying restricted stock unit award granted and how does it vest?

The restricted stock unit award was granted on February 26, 2024. 33% of the shares vested on the one-year anniversary of January 15, 2024, and the remaining 67% vest annually over the next two years.

Was the Guardant Health Form 4 transaction an open-market sale?

No. The Form 4 shows a code F transaction where shares were withheld by the company to cover tax obligations related to restricted stock unit vesting, rather than a discretionary open-market sale.